Indofarma Past Earnings Performance
Past criteria checks 0/6
Indofarma's earnings have been declining at an average annual rate of -69.3%, while the Pharmaceuticals industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 0.5% per year.
Key information
-69.3%
Earnings growth rate
-69.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 20.4% |
| Revenue growth rate | 0.5% |
| Return on equity | n/a |
| Net Margin | -63.8% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Indofarma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 684,913 | -437,053 | 239,081 | 0 |
| 30 Jun 23 | 934,019 | -458,094 | 250,205 | 0 |
| 31 Mar 23 | 974,876 | -439,077 | 247,697 | 0 |
| 31 Dec 22 | 1,144,108 | -428,463 | 266,498 | 0 |
| 30 Sep 22 | 2,309,033 | -223,515 | 273,212 | 0 |
| 30 Jun 22 | 2,626,715 | -129,273 | 273,016 | 0 |
| 31 Mar 22 | 2,867,810 | -90,583 | 292,328 | 0 |
| 31 Dec 21 | 2,901,987 | -37,581 | 292,914 | 0 |
| 30 Sep 21 | 2,464,184 | 21,734 | 310,190 | 0 |
| 30 Jun 21 | 2,117,614 | 5,667 | 309,115 | 0 |
| 31 Mar 21 | 1,940,625 | 23,276 | 284,535 | 0 |
| 31 Dec 20 | 1,715,588 | 28 | 261,274 | 0 |
| 30 Sep 20 | 1,524,893 | 23,922 | 213,923 | 0 |
| 30 Jun 20 | 1,437,661 | 27,656 | 211,474 | 0 |
| 31 Mar 20 | 1,371,076 | 8,304 | 212,723 | 0 |
| 31 Dec 19 | 1,359,175 | 7,961 | 225,472 | 0 |
| 30 Sep 19 | 1,437,345 | -32,484 | 259,159 | 0 |
| 30 Jun 19 | 1,542,508 | -57,346 | 271,684 | 0 |
| 31 Mar 19 | 1,580,299 | -46,023 | 275,558 | 0 |
| 31 Dec 18 | 1,592,980 | -32,736 | 274,754 | 0 |
| 30 Sep 18 | 1,594,144 | -17,230 | 266,898 | 0 |
| 30 Jun 18 | 1,569,381 | 7,510 | 253,095 | 0 |
| 31 Mar 18 | 1,572,352 | -19,937 | 253,280 | 0 |
| 31 Dec 17 | 1,631,317 | -46,283 | 270,545 | 0 |
| 30 Sep 17 | 1,582,421 | -51,107 | 267,782 | 0 |
| 30 Jun 17 | 1,684,605 | -43,041 | 284,281 | 0 |
| 31 Mar 17 | 1,681,116 | -32,623 | 302,814 | 0 |
| 31 Dec 16 | 1,674,703 | -17,367 | 289,952 | 0 |
| 30 Sep 16 | 1,695,104 | 8,132 | 274,959 | 0 |
| 30 Jun 16 | 1,630,439 | 2,507 | 266,938 | 0 |
| 31 Mar 16 | 1,628,669 | 6,937 | 259,695 | 0 |
| 31 Dec 15 | 1,621,899 | 6,567 | 266,364 | 0 |
| 30 Sep 15 | 1,384,022 | 5,140 | 263,342 | 0 |
| 30 Jun 15 | 1,456,522 | 28,537 | 259,445 | 0 |
| 31 Mar 15 | 1,421,092 | 19,882 | 257,856 | 0 |
| 31 Dec 14 | 1,381,437 | 1,442 | 269,199 | 0 |
| 30 Sep 14 | 1,489,448 | -28,726 | 327,436 | 0 |
| 30 Jun 14 | 1,378,964 | -95,824 | 373,744 | 0 |
| 31 Mar 14 | 1,369,123 | -81,641 | 373,566 | 0 |
| 31 Dec 13 | 1,337,498 | -54,222 | 348,690 | 0 |
| 30 Sep 13 | 1,095,394 | -38,816 | 309,713 | 0 |
| 30 Jun 13 | 1,097,553 | 26,946 | 269,424 | 0 |
Quality Earnings: INAF is currently unprofitable.
Growing Profit Margin: INAF is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: INAF is unprofitable, and losses have increased over the past 5 years at a rate of 69.3% per year.
Accelerating Growth: Unable to compare INAF's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INAF is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2%).
Return on Equity
High ROE: INAF's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.